(NASDAQ: VTRS) Viatris's forecast annual revenue growth rate of 2.8% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.99%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.36%.
Viatris's revenue in 2026 is $14,299,900,000.On average, 13 Wall Street analysts forecast VTRS's revenue for 2026 to be $17,197,204,682,992, with the lowest VTRS revenue forecast at $16,429,225,604,018, and the highest VTRS revenue forecast at $17,812,048,503,340. On average, 12 Wall Street analysts forecast VTRS's revenue for 2027 to be $17,505,777,986,088, with the lowest VTRS revenue forecast at $16,563,938,575,892, and the highest VTRS revenue forecast at $18,173,585,880,848.
In 2028, VTRS is forecast to generate $17,915,673,866,320 in revenue, with the lowest revenue forecast at $16,743,555,871,724 and the highest revenue forecast at $18,893,206,457,098.